Nintedanib Stada (Nintedanib)

Nintedanib inhibits multiple receptor tyrosine kinases—VEGFR, PDGFR and FGFR. By blocking these receptors it reduces fibroblast activation, angiogenesis and extracellular matrix deposition, which together limit fibrotic remodeling in the lungs and impede the vascular support that tumors need to grow.

The exact dose and dosing schedule are set by the treating physician based on the patient’s indication, liver function, concomitant medications and overall clinical condition. No universal dosing regimen is provided here; prescribers follow the approved label and adjust as needed.

The safety of Nintedanib in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding is not recommended while on therapy.

To request Nintedanib Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

For idiopathic pulmonary fibrosis, the primary alternative is pirfenidone, another antifibrotic agent. While both aim to slow lung function decline, Nintedanib targets a broader range of tyrosine kinases, which may offer additional benefit in systemic sclerosis‑ILD and certain cancer regimens. Choice of therapy depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Stada should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid storing it in areas of high humidity or extreme heat.

The medication is taken orally, usually with food to lessen gastrointestinal discomfort. Capsules or tablets are swallowed whole with a full glass of water. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

The most concerning adverse events include significant liver enzyme elevations that can progress to hepatitis, severe bleeding complications, and rare cases of gastrointestinal perforation. Patients should be monitored regularly for signs of liver dysfunction, bleeding, and abdominal pain that could indicate a perforation.

Nintedanib is contraindicated in individuals with severe hepatic impairment (Child‑Pugh C) and in patients with known hypersensitivity to the active substance or any excipients. Caution is also advised for patients with active bleeding disorders, uncontrolled hypertension, or those taking strong CYP3A4 inducers or inhibitors without appropriate monitoring.